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HOW HUMAN GENETICS CAME TO SA
The hereditary ataxias are characterised by progressive neuro­
degeneration, leading to permanent disability. Symptoms of 
hereditary ataxia typically include a progressive incoordination of 
gait, hands and speech. The inability to coordinate movement has 
a significant impact on the quality of life of patients, as well as their 
family members and caregivers. Furthermore, palliative care and 
management of these individuals comes at a significant cost. Ataxia 
may be inherited in an autosomal dominant, autosomal recessive or 
X­linked manner.[1] The most common forms of dominant inherited 
ataxia are the spinocerebellar ataxias (SCAs) type 1, 2, 3, 6 and 7, 
caused by the expansion of a CAG repeat tract beyond a pathogenic 
threshold. Friedreich’s ataxia (FRDA) is the most common recessive 
ataxia, resulting from the expansion of a GAA repeat within the FXN 
gene.[2] 
The global epidemiology of the hereditary ataxias is largely 
unknown, but a meta­analysis of prevalence studies has led to the 
estimation that an average of 2.7 per 105 individuals are affected 
with autosomal dominant hereditary ataxia.[3] Given the current 
African population estimate of 1.11 billion, approximately 30 000 
Africans may be affected with one of these disorders. Reports on 
the prevalence of the inherited ataxias on the African continent, 
particularly sub­Saharan Africa, have been extremely scarce. Many of 
the existing reports in the literature are not representative of a large 
geographical area, but rather of isolated cases and families. 
The past
In the 1970s, a large family of coloured individuals with autosomal 
dominant ataxia was identified in the Western Cape region of South 
Africa (SA). Of concern at the time was that affected individuals 
often had transmitted the gene before they were aware of the 
condition. There were no genetic tests available at that time. A study 
was undertaken to determine whether or not there were early pre­
symptomatic clinical markers for the condition that could be of value 
for genetic counselling. In an early publication in Brain by Philcox 
et al.,[4] it was documented that defective optokinetic nystagmus 
and absent or abnormal ocular­vestibular responses in association 
with normal cochlear function were an early manifestation of 
the disorder in this family.[4] Additional families with adult­onset 
autosomal dominant ataxia were identified in the neurology units 
at the two academic tertiary hospitals in that region, Groote Schuur 
Hospital (GSH) and Tygerberg Hospital. Subsequent to that early 
study, a large prospective population­based study was undertaken 
by Alan Bryer as part of his PhD project. Pedigrees of individual 
families were carefully documented and both affected and unaffected 
individuals were assessed. Appropriate electrophysiological testing 
and magnetic resonance imaging brain scans were done to phenotype 
selected affected patients. In the early years, an initial conventional 
linkage study was undertaken in the largest family, and this showed 
linkage to the HLA locus on chromosome 6.[5] A multi­locus linkage 
analysis confirmed the assignment of a locus for the disease distal 
to HLA. In 1991 the gene for SCA type 1 (SCA1) was identified 
and shown to be caused by an expanded unstable CAG repeat 
within the gene on chromosome 6p.[6,7] A collaboration with Huda 
Zoghbi from Minnesota confirmed that the local large family had 
the SCA1 mutation. A haplotype­based study later confirmed a 
SCA1 founder effect in the SA coloured population.[8] In the era of 
molecular genetics that followed, further mutations were identified 
for the dominant ataxias. Consequent to the population­based study, 
a predictive testing service for the familial ataxias was established 
at GSH. This study was extended to the other provinces and blood 
samples were received from affected kindred from all over SA since 
1994. 
The present
To date, approximately 1 600 individuals from 1 280 families 
have been referred to the Division of Human Genetics/National 
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Health Laboratory Service (NHLS) for testing for one or more 
of the SCAs. Roughly 20% of these individuals have received a 
confirmed molecular diagnosis of SCA types 1, 2, 3, 6 or 7. The 
distribution of families diagnosed with one of the dominant SCAs 
has not changed remarkably since the first report on 44 families 
in 2003 (Fig. 1, left panel, from Bryer et al.[9]), although a larger 
proportion of families have now been diagnosed with SCA2 
(Fig. 1, right panel, based on 253 families). SCA1 remains the 
most commonly diagnosed form of dominant ataxia in SA. SCA3 
is commonly reported as the most prevalent form of SCA globally. 
However, only 14 SA families have been diagnosed with SCA3 
since the initiation of testing. The high prevalence of SCA7 in 
the SA black African population is another unique feature, which 
has led to numerous local research projects (see Watson et al. 
elsewhere in this edition). 
The information supplied with molecular diagnostic testing referrals 
rarely contains detailed biographical or clinical information. 
However, we estimate that at least 50% of the individuals diagnosed 
with SCA are black African or coloured (a population unique to SA, 
containing an admixture of European, Khoisan, Asian and black 
African ancestries) (Fig. 2, left panel). Since these population groups 
are unique to the sub­Saharan African region, this figure indicates 
that inherited forms of ataxia are prevalent in ‘indigenous’ African 
populations, and not only in individuals of European descent. 
Similarly, over 50% of ataxia patients who remain molecularly 
undiagnosed, are black African or coloured (Fig. 2, right panel).
Additionally, over a period of 15 years of testing, approximately 
327 individuals from 266 families have had molecular testing for 
recessive FRDA. Thirty­seven of these individuals (from 30 families) 
had molecularly confirmed FRDA. To the best of our knowledge, 
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Fig. 2. Population distributions of SA SCA patients (left) and molecularly undiagnosed individuals with ataxia (right).
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Fig. 1. Distribution of SA families diagnosed with SCA types 1, 2, 3, 6 or 7 from the 1990s until 2003 (left) and 2015 (right).
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no individuals of indigenous black African 
ethnic origin have been given a confirmed 
molecular diagnosis of FRDA. The vast 
majority of confirmed FRDA patients in SA 
are of European ancestry, along with a single 
family of Indian origin.
We have shown that inherited forms of 
ataxia are prevalent within African ethnic 
groups. However, published reports on 
the occurrence of these disorders on the 
African continent have been extremely 
scarce (Fig. 3). Although the expected 
prevalence of the inherited ataxias in Africa 
is significantly lower than other widespread 
diseases such as HIV and tuberculosis, the 
potential impact of future research into these 
disorders cannot be ignored. 
The future
While almost 1 600 individuals had been 
referred to our centre for molecular testing 
over a 27­year period, only 21% have received 
a confirmed molecular diagnosis. Firstly, this 
is likely to be an under­representation of 
the number of South Africans affected with 
the SCAs, since financial constraints and 
deficient healthcare infrastructure limit the 
number of clinical referrals from low­income 
and rural areas. Secondly, it is of concern that 
almost 80% of the referred individuals did 
not receive a molecular diagnosis. While this 
may be due to poor or unwarranted clinical 
referrals, it is possible that a proportion of 
these patients are affected with an additional 
type of SCA that does not form part of the 
current testing panel (SCA types 1, 2, 3, 6, 
7, 12, 17 and FRDA). Clinical or familial 
information rarely accompanies biological 
samples, therefore it is unknown whether these 
undiagnosed individuals come from families 
with multiple affected members. It is also 
not known whether any particular population 
group is over­represented in this ‘undiagnosed’ 
cohort, since the ethnicities of only a small 
proportion of this group is known. Studies 
undertaken in other countries may be useful 
in determining whether other types of ataxia 
should be included in the testing panel, but 
the SA population is highly heterogeneous 
and unique, and no other broad SCA­based 
epidemiological investigations have been 
completed in other African countries.
In cases of families with a strong family 
history, but with an unknown genetic cause, it 
may be beneficial to employ next­generation 
technologies such as whole genome or exome 
sequencing. Németh et al.[22] demonstrated 
the utility of this approach by using next­
generation sequencing in an attempt to 
determine the underlying mutations in 
50 patients with familial or early­onset 
ataxia who had previously been tested for 
SCA types 1, 2, 3, 6, 7 and FRDA. Targeted 
capture performed on 117 candidate 
genes revealed 13 pathogenic mutations 
(nine of which were novel) in the patient 
cohort, indicating that the inclusion of this 
strategy may be advantageous in diagnostic 
laboratories. However, it should be noted 
that this method may be accompanied by 
new challenges, such as increased cost and 
difficulty in interpreting the pathogenicity of 
new variants, therefore it may be some time 
before it is adopted into routine practice in 
resource­limited countries.
As part of future studies, we will contact 
neurologists throughout sub­Saharan Africa, 
requesting referrals of individuals with 
suspected forms of inherited ataxia. These 
patients will be tested for SCA types 1, 2, 
3, 6, 7 and FRDA. We will then employ 
next generation sequencing technologies 
to identify the genetic causes of ataxia in 
patients without mutations at the previously 
mentioned loci. By achieving these aims, 
we hope to develop a project called ‘Ataxia 
Africa’ – a network of clinicians and 
scientists working together to identify and 
diagnose patients with ataxia on the African 
continent.
Conclusion
To the best of our knowledge, the NHLS 
laboratory at GSH in Cape Town is the 
only laboratory offering a molecular 
diagnostic service for the inherited ataxias 
on the African continent. Additionally, 
the Division of Human Genetics at the 
University of Cape Town (UCT) is the only 
research group in Africa investigating this 
group of disorders, spanning a period of 
almost five decades. A large number of 
individuals and families would benefit from 
increased awareness, molecular testing and 
research for the inherited ataxias in Africa. 
A confirmed molecular diagnosis can enable 
more appropriate clinical management of the 
affected individuals, and family members 
can be counselled with regard to their own 
risk, as well as the risk for current and 
future offspring. Additionally, individuals 
with a confirmed diagnosis may be eligible 
for future clinical trials and therapeutic 
interventions. 
Fig. 3. Published reports of African families with inherited ataxia (SCA types 1, 2, 3, 6, 7 or unidentified 
‘inherited ataxia’). Circles represent the number of described families per country.[10­21] 
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